Trastuzumab-conjugated MSN nanoparticles were utilized for the co-delivery of docetaxel and siRNA against HER2 (siHER2) in a drug-resistant orthotopic HER2+ invasive ductal carcinoma model [115]. The gene discussed is ERBB2; the disease is invasive ductal breast carcinoma.